Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Multiple Myeloma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Leukemia 23Lymphoma 20Recurrence 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 13Neoplasms, Plasma Cell 11Lymphoma, Non-Hodgkin 11Waldenstrom Macroglobulinemia 9Lymphoma, Follicular 9Immunoglobulin Light-chain Amyloidosis 9Hodgkin Disease 9Breast Neoplasms 9Vomiting 8Neoplasms 8Nausea 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large B-Cell, Diffuse 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Amyloidosis 6Leukemia, Myeloid, Acute 5Smoldering Multiple Myeloma 4Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Large-Cell, Immunoblastic 4Lung Neoplasms 4Blast Crisis 4

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Sarcoma × Calcium Dobesilate × Clear all
NCT01490060 2016-04-11

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

M.D. Anderson Cancer Center

Phase NA Completed
47 enrolled 6 charts
Sarcoma

Nausea, Neoplasms, Sarcoma, Vomiting

NCT00410488 2013-03-22

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

M.D. Anderson Cancer Center

Phase NA Completed
51 enrolled 5 charts
Sarcoma

Nausea, Sarcoma, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡